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OBJECTIVES: Atopic dermatitis is one of the most common chronic inflammatory
skin diseases. It has an estimated prevalence of between 5 and 30% in children, and
is steadily increasing in industrialized countries. Pruritus, xerosis and inflamma-
tion are the main symptoms. METHODS: The ABS questionnaire (Atopy Burden
Score) consists of 19 items, structured around 5 components (Everyday Life, Lei-
sure, Family Life, Budget, Work and Privacy). It was distributed to a random sample
of families consulting at the Necker Hospital. The ABS was accompanied by SF12
and PGWBI to obtain internal and external validation, and by the PO-SCORAD to
assess the level of severity. RESULTS: 58 were considered evaluable. Internal va-
lidity was measured by Cronbach’s alpha, which is equal to 0.81, reflecting a good
homogeneity of the 19 questionnaire items. The mean PGWBI score is 51.8214.28.
The scores are significantly different depending on the severity of the atopy. Fam-
ilies’ quality of life, measured using the SF12, revealed no deterioration in the
physical component (52.837.08). The ABS score is correlated with the scores of the
questionnaires used, thus confirming external validity.The mean score calculated
from the ABS is 48.1718.36. The score increases with the severity of the atopy.A
statistically significant difference is observed between the three severity groups,
i.e. mild, moderate and severe, with scores of 30.6310.89, 42.5515.72 and
62.6213.59 respectively. Each of the five components is also correlated with the
severity of atopy, which opens the door for more detailed analyses of sensitivity to
change. CONCLUSIONS: The internal and external validity of our questionnaire
were confirmed. ABS is correlated with the severity of atopy. This is currently being
done as part of a program aimed at evaluating the therapeutic education and
treatment of children in hydrotherapy centers. Following cultural and linguistic
validation, the ABS is now available in US English, Spanish, German and Italian.
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OBJECTIVES: The Alcohol Timeline Followback (TLFB), developed in English (US), is
a drinking assessment method that obtains estimates of daily drinking. Using a
calendar, people provide retrospective estimates of their daily drinking over a spec-
ified time period that can vary up to 12 months from the interview date. Several
memory aids can be used to enhance recall, such as 24 key dates and country
specific holidays for calendar year 2012 serving as anchors for reporting drinking,
or use of standard drink conversion. The objective of this study is to present the
translation of the TLFB in Czech, Slovak, Italian, and Hungarian. METHODS: The
following translation method was used: concept definition, forward translation in
the target languages, backward translation and test on five individuals (cognitive
interviews) in each country. RESULTS: Difficulties encountered during the process
were twofold: 1) ensuring that the standard drink conversions were correct, i.e.,
reflecting US standards, and culturally appropriate, and 2) adapting the 24 US key
anchor dates to each country. For the standard drink conversion, the main change
was the use of the metric system instead of the US customary units, i.e., use of liter
and sub-units instead of ounces. In addition, quantities had to be adapted to fit
cultural uses. For instance, in Slovakia and Czech Republic, “one 12 oz can/bottle of
beer” was adapted to “one beer in a can / bottle of 0.5 liter.” Thirteen anchor dates
in the US calendar had to be deleted in all countries, e.g., Martin Luther King day
(01/16/2012) or President’s Day (02/20/2012), as culturally inappropriate. Other key
dates were added, e.g., Labor Day (05/01/2012) or Easter Monday (04/09/2012) in all
four countries. Patients were key in discussing changes or proposing solutions.
CONCLUSIONS: The multistep process proved crucial to ensure cultural relevance
and cross-cultural equivalencies across different languages.
PRM125
WHOSE VALUES IN HEALTH? A COMPARISON OF ADULT AND ADOLESCENT
VALUES FOR THE CHU9D AND AQOL-6D
Ratcliffe J
Flinders University, Daw Park, South Australia, Australia
OBJECTIVES: The Child Health Utility-9D (CHU9D) and Assessment of Quality of
Life-6D (AQOL-6D) currently represent the only two generic preferences based in-
struments developed for application in the economic evaluation of new health
technologies with both adult and adolescent specific scoring algorithms attached
to them. The main objective of this study was to compare and contrast the appli-
cation of adult and adolescent scoring algorithms for the CHU9D and AQOL-6D in
valuing the health of a community based sample of adolescents.METHODS:A web
based survey including the CHU9D and the AQOL-6D was developed for adminis-
tration to adolescents residing in Australia, aged 11-17 years (n500). Individual
responses to both instruments were converted to health state utility values by
applying [1] adult and [2] adolescent scoring algorithms pertaining to each
instrument. RESULTS: Both the AQOL-6D and CHU9D discriminated well according
to health status and long standing illness regardless of the scoring algorithm em-
ployed. However, important discrepancies were found in that employment of the
adolescent algorithm resulted in consistently lower mean health state values for
the CHU9D but consistently higher mean health state values for the AQOL-6D
relative to employment of their respective adult algorithms and these differences
were found to be statistically significant for both instruments (p0.05).
CONCLUSIONS: The findings from this study concur with an expanding evidence
base highlighting discrepancies in adult and adolescent values for identical health
states. The differences in adolescent and adult values were more profound for the
CHU9D, particularly in relation to mental health impairment states, and may be
significant enough to strongly affect the findings of cost effectiveness studies and
ultimately health care policy. There are important differences between both the
CHU9D and AQOL-6D descriptive systems and the methods of valuation utilized for
each instrument which may impact on the health state utility values generated by
each scoring algorithm.
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OBJECTIVES: To value SF-12v1 outcomes from the perspective of US adults
METHODS: The paired comparisons of the SF-12v1 items were incorporated into a
larger, online survey of US health preferences using an invitation-only panel of US
respondents. This pivoted discrete choice experiment (DCE) collected 28,080 re-
sponses on 408 pairs from 936 respondents. The quantal response model includes
an additive multi-attribute regression within a stacked logit distribution to allow
for excess kurtosis due to satisficing. RESULTS: On a quality-adjusted life year
scale, 30 out of 31 decrements were significantly non-zero at 0.05 significance level.
The only insignificant decrement, LE2, represented the decrease in energy from
“You have a lot of energy all of the time” (i.e., manic) to “You have a lot of energy
most of the time.” The value of pits was 0.1532 QALY (95% CI 0.1022,0.1970) and was
significantly better than dead (0). CONCLUSIONS: This is the first national valua-
tion study of the SF-12v1 descriptive system. Instead of reducing domains of com-
plex descriptive systems to single items (e.g., SF-36v1), DCE allows for choice-based
valuation of all outcomes, regardless of the number of items.
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OBJECTIVES: To undertake a detailed review of the existing use of utility scores in
models evaluating the cost-effectiveness of mental health conditions. The study
also aimed to identify the key issues and challenges that are faced by decision
makers attempting to evaluate the benefits of treatments for mental health.
METHODS: A detailed review was undertaken to identify a wide range of studies
that used modelling techniques to estimate the cost-effectiveness of interventions
for different mental health conditions. The review included studies of treatments
for bi-polar disorder, schizophrenia, depression, anxiety, dementia, eating disor-
ders. The review determined whether each model contained utility data and how
those utility data were derived and reported. Quality grades were assigned to each
study based on the appropriateness of use of the utility data. RESULTS: Nearly all
cost-effectiveness models in mental health contained utility-based outcomes,
such as quality-adjusted life years. However, the quality of data used to generate
those outcomes varied considerably, and many studies contained poor data or data
used in an inappropriate manner. In addition to the expected limitations of instru-
ments used to derive quality of life scores, common misuses of data included: 1)
inappropriate timing of elicitation (for instance, applying quality of life scores at
diagnosis to the whole duration of the model); 2) failing to account for comorbidi-
ties and confounding factors; 3) assumptions around missing data; and 4) failing to
account for the patient’s history when defining their current health state.
CONCLUSIONS: The use of utility data in mental health models varies widely, and
most models cannot be considered to provide reliable and robust data. For models
to be useful to decision makers, it is recommended that a consistent approach
toward measuring quality of life in patients with mental health conditions should
be used where possible.
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OBJECTIVES: In its guidance on the use of PRO measures, the FDA specifies the
areas to be addressed in PRO documents provided for review. Regarding language
translation, four areas are listed: (A) Process used to translate and culturally adapt
the instrument for populations that will use them in the trial; (B) Description of
patient testing, language- or culture-specific concerns, and rationale for decisions
made to create new versions; (C) Copies of translated or adapted versions; and (D)
Evidence that content validity and other measurement properties are comparable
between the original and new instruments. The objective of this study is to present
the development of an evidence tracking tool to organize the evidence generated
during the translation of a PRO instrument to comply with the FDA review
requirements. METHODS: 1) Review of the process used to translate PRO instru-
ments, and of the evidence provided during the translation process; 2) Organiza-
tion of the evidence according to the four areas listed in the FDA guidance (exclud-
ing measurement properties); and 3) Development of a standardized tool to present
this information.RESULTS:The translation evidence tracking tool is a table divided
into three parts. Part 1 (translation background information) gathers the informa-
tion requested in areas A and C. Part 2 (translation report) provides the evidence
required in area B. Part 3 (content validity) concerns the comparability of content
validity. For this part, it was assumed that comparability will depend on: (1) A clear
definition and understanding of the concepts to be translated; and (2) The involve-
ment of trained professionals. Hyperlinks are provided in each part of the table to
lead to the evidence documents required for each area listed by the FDA.
A483V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
